A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Oct 2015.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History